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Benzyl vinylogousAbstract Phosphodiesterases are a diverse family of enzymes that play a key role in regulating
intracellular levels of the second messengers cAMP, cGMP and ultimate cell function. Selective
PDE3B inhibitors were recognized to prevent oocyte maturation. In search of effective PDE3B
inhibitors, the present study deals with 3D QSAR analysis on previously reported benzyl vinylogous
derivative. The comparative molecular ﬁeld analysis (CoMFA) studies resulted in reliable and
remarkable computational models. The obtained CoMFA model showed high predictive ability
with q2 = 0.556, r2 = 0.936 and standard error of estimation (SEE) = 0.231, explaining a majority
of the variance in the data with four principal components. The result of the present study shows
good correlation between descriptors and biological activity. On the basis of statistical signiﬁcance
of the generated model the results can be utilized in the design of new more potent benzyl vinylo-
gous derivatives as PDE3B inhibitors.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Phosphodiesterases (PDEs) are intracellular enzymes that spe-
ciﬁcally catalyze the hydrolysis of secondary messengers like
cAMP and cGMP (Conti, 2000; Ahmad et al., 1999; Corbin
and Francis, 1999; Schmidt et al., 1999). These secondary mes-
sengers contribute in the formation of AMP and GMP respec-tively, which plays a key role in a variety of functional
responses to hormones and other cellular transmitters includ-
ing vascular resistance, cardiac output, visceral motility, im-
mune response, inﬂammation, neuroplasticity, vision and
reproduction. PDEs comprise a large group of enzymes orga-
nized into 11 distinct families (PDE families PDE1–PDE11)
based on their different gene families encoding for the structur-
ally related, functionally distinct and highly regulated enzymes
(Cortijo et al., 1993; Rabe et al., 1993; Hidaka and Endo,
1984).
PDE3 ﬁrst named cAMP–PDE or cGMP-inhibited PDE
that is characterized by its high afﬁnity for cAMP and its
capacity to hydrolyze both cAMP and cGMP. PDE3 has at
least two different gene products: PDE3A and PDE3B are
structurally similar but positions on different sites. PDE3A is
mainly found in the oocyte, platelet, heart and vascular
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cytes, hepatocytes, spermatocytes, kidney, beta cells, T-lym-
phocytes and macrophages. A number of PDE3B inhibitors
have been shown to successfully suppress oocyte nuclear mat-
uration without affecting follicle rupture after gonadotropin
stimulation in rats (Cruickshank, 1993; Degerman et al.,
1997; Erherdt and Chou, 1991).
Quantitative structure activity relationship is an attempt to
correlate structural or property descriptors of compounds
quantitatively with biological activities (Ravichandran et al.,
2007a,b). These physiochemical descriptors include parameters
to account for hydrophobicity, topology, electronic properties
and steric effects which are determined by computational
methods, if such a relationship holds true an equation can be
drawn up which quantiﬁes the relationship and allow the
medicinal chemist to say with some conﬁdence that the prop-
erty has an important role in the distribution or mechanism
of the drug (Ravichandran et al., 2008a,b). Recent trends in
3D QSAR have focused on the development of procedures
that allow selection of optimal variables from the available
pool of descriptors of chemical structures i.e., ones that are
most meaningful and statistically signiﬁcant in terms of corre-
lation with biological activity.
The most popular 3D QSAR methods are comparative
molecular ﬁeld analysis (CoMFA). The CoMFA methodology
based on the genetic algorithm ultimately allows one to design
and predict activities of molecules. The CoMFA method in-
volves the generation of a common three dimensional lattice
around a set of molecules and calculation of steric and electro-
static interaction energies at the lattice points (Vaidya et al.,
2011; SYBYL, 2008; Prashanthakumar and Nanjan, 2010).
Herein, we used the structures of 29 benzyl vinylogous anal-
ogous and their PDE3B inhibitory activities to establish 3D
QSAR model by CoMFA technique provided by SYBYL 6.9
molecular modeling software (Edmondson et al., 2003).
In conclusion of our earlier attempt to develop a predictive
CoMFA model for designing new compounds, here we report
CoMFA of benzyl vinylogous derivatives as potent PDE3B
inhibitory agents.
2. Materials and methods
2.1. Data set
QSAR studies were performed on a series of benzyl vinylogous
derivatives having twenty-nine compounds, out of these
twenty-nine, ﬁfteen have a dihydropyridazone ring and the
fourteen having dimethylpyrazolones are listed below
(Table 1).
2.2. Molecular structure optimization and alignment
Structures of the PDE3B inhibitors were built on the work-
space of Silicon Graphics work station molecular modeling
software SYBYL version 6.9. The geometry-optimization
was carried out using the standard Tripos molecular mechanics
force ﬁeld with a distance-dependent (1/r) dielectric function
and the Powell conjugate gradient algorithm with a conver-
gence criterion of 0.001 kcal/mol. Partial charges for all the
molecules were assigned using Gasteiger–Huckel method.
After allocating the partial charge, molecules were submittedfor a conformational search protocol using multi-search meth-
od with the following settings: maximum cycles 400, maximum
conformers 100, energy cut-off 30 kcal/mol, number of hits 12,
maximum rms gradient 3.0 and tolerance 0.40. The conformer
of the most active compound with the lowest energy was then
used.
For 3D QSAR alignment of molecules is the most subjec-
tive and critical step. In the present study, compound having
highest pIC50 (compound No. 1e) served as a template, and
all molecules were superimposed on the template via ﬁeld ﬁt
alignment technique. Fig. 1 shows the ﬁeld ﬁt alignment of
the molecules. Following alignment the molecules were placed
within a lattice that extended 4 A˚ units beyond the aligned
molecules in all directions with a grid step size of 2 A˚, using
a probe sp3 hybridized carbon atom with +1 charge and
Van der Waals radius of 1.52 A˚ was employed.
2.3. CoMFA analysis
For CoMFA analysis steric and electrostatic ﬁelds were gener-
ated with the distant-dependent dielectric constant using a cut-
off of 30 kcal/mol to truncate both steric and electrostatic ﬁeld
energies. All models were generated using partial least square
regression analysis (PLS) and cross validation was done with
leave one out (LOO) method with 2.0 kcal/mol column ﬁlter.
As for the modeling methods, the CoMFA energies ﬁelds were
used as independent variables with the pIC50 activity value as a
dependent variable. The statistical signiﬁcance and predictive
ability of resulting model was assessed using cross validated
r2, also called q2. The conventional r2 was considered as a mea-
sure of the predictive ability within the training set, while the q2
has been considered as a measure of predictive ability outside
the training set or test set.
3. Results and discussion
Three-dimensional structure building and all the modeling
were performed by comparative molecular ﬁeld analysis
(CoMFA) on a Silicon Graphics work station using the SYB-
YL 6.9 molecular modeling software from Tripos Inc. (St.
Louis, MO, USA).
CoMFA model with signiﬁcant internal and external pre-
dictive ability was selected with a high q2 value of 0.556 at
the optimum number of components as four. The non-cross-
validated r2 (LOO) value was 0.936 with standard error of esti-
mate (SEE) 0.231. This model also indicates statistical signiﬁ-
cance >99.0% with covariance ratio (F) of 62.78 (Table 2).
The correlation between experimental and predicted activity
with residual activity for both training and test set of com-
pounds are shown in Table 1 and represented graphically in
Fig. 2. These results authenticate the good prediction ability
of the generated 3D QSAR model. The CoMFA contour plots
show the generated steric and electrostatic ﬁelds around
aligned molecules with 42.8% and 57.2% ﬁeld contribution
respectively (Fig. 3). The greater size of blue-red region than
yellow-green region indicates a greater contribution of electro-
static ﬁelds (57.2%) than steric ﬁelds (42.8%) in the determina-
tion of biological activity. Greater values of ‘‘Bio-Activity
Measurement’’ are correlated with more bulky near green, less
bulky near yellow, more electronegative near red and less elec-
tronegative near blue.
Table 1 Structures of compounds used in the study with their biological activities.
Molecule Ar R Actual pIC50 CoMFA predicted pIC50 CoMFA residual
1a 2-MeOPh H 9.41 9.28 0.13
1b 2-CF3Ph H 9.08 9.21 0.13
1c 3-FPh H 7.55 7.6 0.05
1d 3-BrPh H 9.02 9.01 0.01
1e 3-IPh H 9.48 9.48 0
1f 3-NO2Ph H 8.51 8.35 0.16
1g 4-MeOPh H 8.64 8.73 0.09
1h 4-NO2Ph H 7.62 7.62 0
1i Ph 2-Me 7.66 8.67 0.99
1j Ph 3-Me 8.43 8.40 0.03
1k Ph 2-Et 6.99 7.79 0.8
1l Ph 2-F 8.79 8.62 0.17
1m Ph 3-F 8.92 9.07 0.09
1n Ph 2-Cl 7.33 8.35 1.02
1o Ph 2,5-DiF 8.79 8.85 0.06
2a Ph H 7.27 8.06 0.79
2b Ph 2-Me 7.42 7.24 0.18
2c 3-CNPh 2-Me 6.89 6.94 0.05
2d Ph 2-F 7.7 7.8 0.1
2e 3-CNPh 2-F 7.16 7.21 0.05
2f 3-NO2Ph 2-F 6.82 7.42 0.6
2g 2-ClPh 2-F 8.14 8.19 0.05
2h 2,6-Cl2Ph 2-F 7.66 7.32 0.34
2i 2-FPh 2-F 7.8 7.86 0.06
2j 3-FPh 2-F 7.37 7.43 0.06
2k 4-FPh 2-F 7.2 7.03 0.17
2l 3-NO2Ph 2-Cl 6.26 6.44 0.18
2m 2-ClPh 2-Cl 7.11 7.37 0.26
2n 3-CNPh 2,3-F2 8.12 8.12 0
Figure 1 Field ﬁt alignment of benzyl vinylogous derivatives.
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Table 2 PLS statistics results of 3D QSAR model of CoMFA.




























Figure 2 Correlation between the experimental and predicted
activities of the developed CoMFA model.
S112 S. Jain et al.A large green counter near fourth position substituted
dihydropyridazinones or dimethylpyrazolones of benzyl ring
indicates that the bulky substitutions favor the activity at the
mentioned position therefore compounds of dihydropyridazi-
nones derivatives (compound No. 1a–1o) showed greater
activity as compared to dimethylpyrazolones derivatives (2a–
2n). The yellow region near the 3rd position of benzyl ring
derivatives suggests that biological activity will be decreased
by introducing a bulky group at this position. Thus the pres-Figure 3 CoMFA contour plots for steric and electrostatic regions.
the yellow counter indicates those regions where bulky groups are not
contribution, whereas blue counters indicate the region where electropence of small group substitution or unsubstitution (such as
the presence of methyl in compound 1j) enhances the biologi-
cal activity.
Similarly, blue contour near 4-oxocyclohex-1ethylamino
(Ar substitution) substitution indicates that substitution with
less electronegative groups favors activity (3-IPh in com-
pounds 1e). In spite of this red region near the 1st and 4th po-
sition substituted dihydropyridazinones or
dimethylpyrazolones of benzyl ring favors more electronega-
tive group substitution for improved biological activity.
4. Conclusion
The 3D QSAR studies of a set of recently synthesized vinylo-
gous derivatives have been successfully performed using CoM-
FA method. The contour plots of CoMFA analysis provides
many useful insights into the relationship between structural
features and biological activity, and provides the information
in designing novel compounds with increased PDE3B inhibi-
tion activity.
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